Novo Nordisk upgrades full-year guidance
Following a strong Q1 sales performance, Danish pharmaceutical giant Novo Nordisk has adjusted its 2022 outlook upward. (Updated)
by christopher due karlsson, translated by daniel pedersen
Novo Nordisk has released its Q1 financial report, in which the company announces its new sales growth outlook for 2022 of 10–14 percent in constant exchange rates, up from earlier 6–10 percent, the company reports in a Friday press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
